"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.631.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- ANG-(1-8)Octapeptide
- Angiotensin-(1-8) Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Angiotensin II, Isoleucine(5)-
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- Isoleucine(5)-Angiotensin
- Isoleucyl(5)-Angiotensin II
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in this website by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 18 | 11 | 29 |
| 2018 | 12 | 5 | 17 |
| 2019 | 4 | 2 | 6 |
| 2020 | 13 | 16 | 29 |
| 2021 | 7 | 2 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles.
-
Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021; 16(9):e0257016.
-
Neurological effects of elevated levels of angiotensin II in COVID-19 patients. Hum Cell. 2021 Nov; 34(6):1941-1942.
-
Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19. Biomolecules. 2021 07 03; 11(7).
-
Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients. Front Immunol. 2021; 12:625732.
-
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. Front Immunol. 2021; 12:649122.
-
Immunopathogenesis and immunobiology of SARS-CoV-2. Infez Med. 2021 Jun 01; 29(2):167-180.
-
Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019. Crit Care Med. 2021 06 01; 49(6):e613-e623.
-
Angiotensin II Administration in Patients With COVID-19 Shock. Crit Pathw Cardiol. 2021 06 01; 20(2):100-102.
-
A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure. Am J Physiol Lung Cell Mol Physiol. 2021 07 01; 321(1):L213-L218.
-
Endocrine and metabolic aspects of COVID-19. Endokrynol Pol. 2021; 72(3):256-260.